to PanCAN.
Anne-Marie is a senior executive with extensive experience in the biopharmaceutical industry. In her most recent role as executive vice president and chief medical officer at Rigel Pharmaceuticals, she led the development of new drugs for auto-immune diseases and was responsible for getting their first drug approved.
Anne-Marie has lost several friends to pancreatic cancer and another is currently battling the disease. She looks forward to bringing her expertise to large-scale, life-changing initiatives like PanCAN’s Precision Promise℠ to improve treatment options for pancreatic cancer patients.
Here, we share more about Anne-Marie’s background, interests and what brought her to PanCAN.